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Summary
 
T helper cell type 1 (Th1) and 2 (Th2) are central to immune regulation. However, no stable
 
cell surface marker capable of distinguishing and separating these two subsets of CD4
 
1
 
 cells has
yet been found. Using differential display PCR, we have identified a gene encoding a cell
membrane bound molecule, originally designated ST2L, T1, DER4, or Fit, expressed constitu-
tively and stably on the surface of murine Th2s, but not Th1s even after stimulation with a
range of immunological stimuli. Antibody against a peptide derived from ST2L strongly and
stably labeled the surface of cloned Th2s but not Th1s, and Th2s but not Th1s derived from
 
naive T cells of ovalbumin T cell receptor–
 
a
 
/
 
b
 
 transgenic mice. Three-color single cell flow
cytometric analysis shows that cell surface ST2L coexpressed with intracellular interleukin (IL)-4,
but not with interferon (IFN)-
 
g
 
. The antibody selectively lysed Th2s in vitro in a comple-
ment-dependent manner. In vivo, it enhanced Th1 responses by increasing IFN-
 
g
 
 production
and decreasing IL-4 and IL-5 synthesis. It induced resistance to 
 
Leishmania major
 
 infection in
BALB/c mice and exacerbated collagen-induced arthritis in DBA/1 mice. Thus, ST2L is a sta-
ble marker distinguishing Th2s from Th1s and is also associated with Th2 functions. Hence, it
may be a target for therapeutic intervention.
 
C
 
D4
 
1
 
 T cells can be divided into Th1 and Th2 subsets,
the balance of which frequently determines the out-
come of infectious and autoimmune diseases (for review
see references 1 and 2). Th1s characteristically produce
IFN-
 
g
 
 and activate macrophages to kill intracellular patho-
gens and can cause inflammatory diseases. Th2s produce
IL-4 and IL-5 and are associated with allergic reactions in-
volving IgE, eosinophils, and basophils (for review see ref-
erence 3). However, a stable cell surface marker distin-
guishing Th1s and Th2s thus far has not been found nor is
the mechanism for selective cytokine induction known.
Recently, CD30 was reported to be expressed transiently
and preferentially on cloned human Th2s compared with
Th1s (4). Message for IL-12 receptor 
 
b
 
2 subunit was found
to be induced on Th1s by IL-12 and IFN-
 
g
 
 (5, 6). How-
ever, the stability and in vivo relevance of these molecules
remained to be ascertained. Th1s but not Th2s, are able to
bind P-selectin and L-selectin (7), but the ligands for the
binding are unknown. The eotaxin receptor CCR3 was
found to be selectively expressed by human Th2s (8).
However, this marker is rapidly downregulated after T cell
activation. A stable cell surface marker distinguishing Th1s
and Th2s will not only finally settle the debate on the va-
lidity of the classification of these T cell subsets, but will
greatly facilitate the investigation of Th1–Th2 interaction
by selective sorting of pure population of cells for func-
tional experimentations.
We now report the identification of a stable cell surface
marker expressed on Th2s, but not Th1s. Using differential
display PCR (9) comparing a panel of Th1 and Th2 clones,
we identified a gene that is expressed on Th2s but not
Th1s. This gene has complete homology with a gene origi-
nally designated as 
 
ST2L
 
 (10), 
 
T1
 
 (11), 
 
DER4
 
 (12), or 
 
Fit
 
-1
(13). This gene (henceforward called ST2L) is transcribed
in the bone marrow of adult mice and in cultured hemato-
poietic cells as a 5-kb messenger RNA (mRNA)
 
1
 
 in re-
sponse to proliferation-inducing stimuli. It is expressed in
major hematopoietic organs, but restricted to only a few
cell types. The gene encodes a receptor-like molecule of
the Ig superfamily homologous to the type I IL-1 receptor,
but does not bind any of the three known IL-1 species
 
1
 
Abbreviations used in this paper:
 
 CIA, collagen-induced arthritis; DD-PCR,
differential display PCR; mRNA, messenger RNA.
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(14). Antibody against the extracellular domain of ST2L
stably labeled Th2s, but not Th1s. It lysed Th2s with com-
plement in vitro and enhanced Th1 responses in vivo. The
antibody increased resistance to 
 
Leishmania major
 
 infection
in BALB/c mice and exacerbated collagen-induced arthritis
in DBA/1 mice. Thus, ST2L could be an important cell
surface target for the manipulation of immune responses.
 
Materials and Methods
 
Cell Lines and Tissue Culture.
 
T cell clones used were as fol-
lows: Dorris (specific for hen egg lysozyme, H-2
 
k
 
) and D10 (spe-
cific for conalbumin, H-2
 
k
 
) were obtained from American Type
Culture Collection (Atlanta, GA). X4, X9, X12, X17, D2.2, and
D2.3 were cloned and maintained as described previously (15).
The X and D series of clones are all H-2
 
d
 
 restricted and specific
against group A streptococcal M protein. The cell lines were
maintained by periodic antigen stimulation with the appropriate
irradiated antigen-presenting cells followed by expansion in me-
dium containing IL-2. For the derivation of naive T cell lines,
CD4
 
1
 
 cells were purified from the spleen of OVA TCR-
 
a
 
/
 
b
 
transgenic mice (D011.10; reference 16) by negative selection as
described previously (17). They were cultured with OVA peptide
(OVA
 
323-339
 
) and irradiated BALB/c spleen cells in the presence
of IL-12 plus anti–IL-4 (for Th1 line) or IL-4 (for Th2 line) for
6 d (17).
 
Differential Display PCR.
 
This was performed (9) using RNAim-
age kit (GenHunter Corp., Brookline, MA). Total RNA was pu-
rified from Th1 or Th2 clones and treated with DNase I (Gen-
Hunter Corp.) to remove any trace of DNA. Purified RNA (1 
 
m
 
g)
was transcribed into cDNA using MMLV reverse transcriptase.
The cDNA was amplified by AmpliTaq DNA polymerase (Per-
kin-Elmer Corp., Norwalk, CT) with 50 pairs of primers (Gen-
Hunter). 40 cycles of PCR reaction were performed in the pres-
ence of [
 
35
 
S]dATP (New England Nuclear, Boston, MA), and
products separated in 6% sequencing gels under denaturing con-
ditions. DNA fragments from Th1s and Th2s were then com-
pared. Bands unique to Th1 or Th2 clones and longer than 150
bp were excised from the dried gel, extracted by boiling in 100 
 
m
 
l
of double-distilled H
 
2
 
0, and precipitated with ethanol in the pres-
ence of glycogen. DNA was further amplified with the original
set of primers used to generate the particular band by the same
thermal cycle conditions. PCR products were electrophoresed in
1.5% agarose ethidium bromide gel to confirm the band size be-
fore cloning into PCRII vector (Invitrogen, Carlsbad, CA) and
sequenced using M13R and M13(-20)F primers.
 
Reverse Northern Blot.
 
This was used to screen and confirm
the differentially expressed mRNA (18) using a ReversePrime Kit
(GenHunter Corp.). Denatured PCR products (100 ng) were dot
blotted onto duplicate nylon membranes with the slot-blot filtra-
tion manifolds (Hoefer, San Francisco, CA), using murine IL-5
and 
 
b
 
-actin cDNA as controls for specificity and equal loading,
respectively. Membranes were UV cross-linked and hybridized
with equal amounts of Th1 or Th2 cDNA probes (10
 
6
 
 cpm). The
probes were prepared from 10–50 
 
m
 
g of each of Th1 or Th2
RNA by reverse transcription using 1,000 units of MMLV re-
verse transcriptase in the presence of 
 
a
 
-[
 
32
 
P]dCTP and T20
primer. The duplicate membranes were hybridized with Th1 or
Th2 probes in 6 
 
3
 
 SSC, 5x Denhardt’s solution, 0.5% SDS, and
100 
 
m
 
g/ml of denatured salmon sperm DNA at 60
 
8
 
C overnight.
The membranes were then washed, exposed for 4–8 h to a x-ray
film, and the hybridization patterns compared.
 
Northern Blot.
 
Total RNA was isolated from cells by RNA-
ZolB and was separated (20 
 
m
 
g/lane) in 1% formaldehyde agarose
gels, blotted to nylon membrane, and hybridized with the 3
 
9
 
 ter-
minal cDNA fragment of ST2L, and labeled with 
 
a
 
-[
 
32
 
P]dATP.
The cDNA fragment was cloned from D10 cells by differential
display PCR (DD-PCR) using the primer pair: AAGCTTTT-
TTTTTTTA and AAGCTTCAGCAGC (designated H-T11A
and H-AP34, respectively; GenHunter Corp.).
 
Reverse Transcriptase PCR Southern Blot.
 
Primers for amplify-
ing ST2L were: sense, ACTTTGTTCACCACACTCTGC; an-
tisense, AACAGATGCCGTCTTGGAGGC (product of 
 
z
 
450
bp). Primers for 
 
b
 
-actin were: sense, GTGGGCCGCTCTAG-
GCACCAA; antisense, CTCTTTGATGTCACGCACGATTTC
(product of 
 
z
 
540 bp). PCR products were separated in 1% agarose
gels. Membranes were hybridized with internal probes (ST2L, ATT-
GAAATGGAGCCTCTGGGTGAGGCAAGC; 
 
b
 
-actin, CAG-
AGCAAGAGAGGTATCCTGACCC) labeled with 
 
g
 
-[
 
32
 
P]dATP
using T4 polynucleotide kinase.
 
Anti-ST2L Antibody.
 
A rabbit was immunized with the pep-
tide corresponding to residues 267–287 of ST2L. The peptide
was selected to have no homology with IL-1 receptor, spanning
the hydrophilic region and within the extracellular domain of
ST2L. The rabbit was immunized subcutaneously with 100 
 
m
 
g of
the peptide conjugated to KLH emulsified in complete Freund’s
adjuvant, and boosted sequentially with the peptide-KLH conju-
gate (100 
 
m
 
g) in incomplete Freund’s adjuvant and in saline. Spec-
ificity of the antibody was tested by Western blot against recom-
binant ST2L and by ELISA with peptide-bound 96-well plates.
Total IgG was purified from the immune serum and preimmu-
nized serum by protein A column or by ammonium sulphate pre-
cipitation. Purity of the IgG was 
 
.
 
95% on SDS-PAGE Coo-
massie blue staining.
 
Flow Cytometric Analysis.
 
Cells were incubated with anti-
ST2L antibody (40 
 
m
 
g/ml) followed by FITC-conjugated don-
key anti–rabbit IgG (SAPU, Paisley, Scotland). All reactions and
washing were carried out at 4
 
8
 
C in PBS containing FCS (5%) and
NaN
 
3
 
 (0.1%), and all antibodies were centrifuged (11,000 
 
g
 
 for 5
min) immediately before use. For three-color staining, cells were
suspended at 10
 
5
 
–10
 
6
 
/ml and stimulated with PMA (50 ng/ml,
Calbiochem Corp., La Jolla, CA) plus ionomycin (500 ng/ml;
Calbiochem Corp.) for 4 h. Brefeldin A (10 
 
m
 
g/ml, Sigma
Chemical Co., St. Louis, MO) was added during the last 2 h.
Cells were then incubated with anti-ST2L antibody or control
IgG followed by biotinylated goat anti–rabbit IgG (Dako Corp.)
and then developed with PerCP-streptavidin (Becton Dickinson,
Mountain View, CA). The cells were then fixed with paraformal-
dehyde (2%), and, after washing, permeabilized at room tempera-
ture with 0.5% saponin (Sigma Chemical Co.) in PBS and FCS
(5%), and stained with FITC-conjugated anti–murine IFN-
 
g
 
(IgG2a; PharMingen, San Diego, CA) and PE-conjugated anti–
murine IL-4 (IgG2a; PharMingen), or FITC- and PE-conjugated
isotype control antibodies (Becton Dickinson). Samples were an-
alyzed on a FACScan
 
Ò
 
 flow cytometer. 
 
Anti-ST2L and Complement-mediated Lysis of T Cells.
 
Cloned T
cell lines (10
 
6
 
 cells in 0.2 ml of culture medium) were incubated
for 30 min on ice with various concentrations of anti-ST2L anti-
body or normal rabbit IgG (clarified by centrifugation). The cells
were washed once and then incubated with guinea pig comple-
ment (1/10 dilution; Harlan Sera-lab, Oxon, UK) for 45 min at
37
 
8
 
C. Cell viability was estimated microscopically (counting
 
.
 
500 cells) by staining with acridine orange and ethidium bro-
mide.
 
Leishmania Infection and Immunological Assays.
 
BALB/c mice 
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Xu et al.
(female, 6–8-wk-old; Harlan Olac, Bicester, UK) were infected
in the right hind footpad with 5 
 
3
 
 10
 
5
 
 stationary phase promas-
tigotes of 
 
L. major
 
 (LV39) and injected intraperitoneally with 250 
 
m
 
g
of rabbit anti-ST2L antibody or normal rabbit Ig. The antibody
was administered for the next 2 d, and then every 3–4 d. Lesion
development was followed by measuring the footpad swelling
(difference between the infected right and uninfected left hind
footpad). The maintenance of parasites, infection, and measure-
ment of disease progression were as described previously (19). At
the end of the experiment, mice were killed by cervical disloca-
tion. Footpad was removed to assay for parasite load by limiting
dilution (20). Draining lymph node cells were harvested and cul-
tured (10
 
6
 
/ml) in vitro with frozen and thawed parasite antigen
(10
 
5
 
–10
 
7
 
 parasite/ml equivalent). Culture supernatant was har-
vested at 48 h and assayed for cytokines by ELISA using paired
antibodies (PharMingen).
 
Induction and Treatment in Collagen-induced Arthritis in Mice.
 
Male
DBA/1 mice (6–8-wk-old, Harlan Olac) were injected intrader-
mally with 200 
 
m
 
g of bovine type II collagen (Sigma Chemical
Co.) in Freund’s complete adjuvant (day 
 
2
 
21). Collagen (200 
 
m
 
g
in PBS) was given again on day 0 by intraperitoneal injection.
Daily injections (intraperitoneal, 200 
 
m
 
g/mouse) of anti-ST2L
antibody or normal rabbit IgG were administered from day 1 for
5 d. Mice were monitored daily for signs of arthritis for which
severity scores were derived as follows: 0, normal; 1, erythema;
2, erythema and swelling; 3, extension/loss of function; total
score 
 
5
 
 sum of four limbs. Paw thickness was measured with a
dial-calliper (Kroeplin, Munich, Germany). Quantification of ar-
thritis was performed as previously described (21, 22). In some
experiments, mice were killed 48 h after antibody treatment and
spleen cells collected and cultured with graded concentrations of
collagen for 48 h in vitro. Supernatants were collected for cyto-
kine assays by ELISA using paired antibodies. T cell proliferation
was analyzed by [
 
3
 
H]thymidine uptake.
 
Results
 
Identification of Differentially Expressed mRNA in Th1s and
Th2s.
 
Total RNA from a panel of four different cloned
Th1 and Th2 lines were compared by DD-PCR. Using 50
primer pairs, 
 
.
 
50 distinct bands were detected (Fig. 1 
 
a
 
), of
which 10 fragments have so far been confirmed to be dif-
ferentially expressed between Th1s and Th2s using reverse
Northern blot (data not shown) and Northern blot analysis.
Nucleotide sequence of one band (Fig. 1 
 
b
 
) has complete
homology with a gene originally designated as ST2L (10).
Northern blot analysis, using the cloned ST2L fragment as
cDNA probe, demonstrated the constitutive expression of
ST2L in all four of the Th2, but not in Th1, lines (Fig. 1 
 
c
 
).
Using the more sensitive reverse transcription PCR South-
Figure 1. Detection of ST2L message in Th2s. RNA from a panel of
four each of different Th1 (Dorris, X4, X9, and X17) and Th2 (D10,
D2.2, D2.3, and X12) clones (resting cells, two wk after antigen stimula-
tion) were extracted and compared by DD-PCR. (a) Two representative
patterns comparing the PCR products from Dorris (Th1) and D10 (Th2)
cells, using two different primer pairs (lanes 1 and 2, H-T11A/H-AP34;
lanes 3 and 4, H-T11G/H-AP34). Arrowhead, the ST2L band. (b) Nucle-
otide sequence of one cDNA present in Th2s, but not in Th1s. This has
complete homology with the 39 terminus of ST2L cDNA. (Data are avail-
able from EMBL/GenBank/DDBJ under accession number D13695.)
The primer (H-T11A/H-AP34) binding sites are underlined. (c) North-
ern blot analysis detected ST2L in D10, but not in Dorris cells. Similar re-
sults were obtained for the other three Th1 and Th2 clones (not shown).
(d) Reverse transcriptase PCR Southern demonstrates the presence of
ST2L message in Th2, but not in Th1, clones. c and d are representative
of three experiments.
Figure 2. (a) Regulation of
ST2L gene expression in vitro
analyzed by reverse transcriptase
PCR Southern. Representative
Th1 (X9) and Th2 (D10) clones
were stimulated for 3, 6, or 12 h
with: lane 1, Con A (2.5 mg/ml);
lane 2, IL-1b; lane 3, IL-5; lane
4, IL-2; lane 5, IL-4; lane 6,
IFN-g (all cytokines were re-
combinant murine proteins ob-
tained from Genzyme [Cam-
bridge, MA] used at 5 ng/ml); lane
7, anti–IFN-g (1 mg/ml); lane 8, anti–IL-4 (1 mg/ml); lane 9, medium
alone; lane 10, anti-CD3 (1.5 mg/ml). Results for 12 h (not shown) were
the same as for 3 h, except no message was detected in X9. D10 cells ex-
pressed ST2L constitutively and stably, whereas X9 cells failed to do so,
except a weak and transient response at 3 and 6 h to IL-5 and anti-CD3,
respectively. (b) Regulation of ST2L expression in T cells by serum. X9
(Th1, lane 1), X4 (Th1, lane 2), and D10 (Th2, lane 3) were cultured for
48 h in medium without serum or IL-2, and then incubated with me-
dium containing 20% FCS. Cells were harvested at that time (0 h) or 6 h
after addition of FCS, and ST2L message was analyzed by reverse tran-
scriptase PCR Southern blot. Serum failed to induce ST2L in Th1s. Re-
sults are representative of four Th1 and Th2 clones.790 T Helper Cell Type 2 Surface Marker
Figure 3. FACSÒ analysis of cell surface expression of ST2L. (a) Th1 (X4) and Th2 (X12) cells were stained with rabbit anti-ST2L antibody (green) or
preimmune rabbit IgG (white) (40 mg/ml) and developed with an FITC-conjugated donkey anti–rabbit IgG. Similar results were obtained for three other
Th1 and Th2 clones (not shown). The staining of Th2s (X12) with anti-ST2L antibody can also be visualized by fluorescent microscopy (3400). Staining
can be blocked by the ST2L peptide (100 mg/ml) and no staining was detected on Th1s (data not shown). (b) Three-color flow cytometric analysis of
Th1 (X4) and Th2 (X12) clones. Th2 (X12) and Th1 (X4) clones were stained for cell surface ST2L (with PerCP), followed by intracellular staining with
anti–IL-4 (with PE) and anti–IFN-g (with FITC). All cells shown in the boxes were activated with PMA/ionomycin. Cells analyzed in boxes (i), (iii), (v)
and (vii) were stained with normal rabbit IgG and isotype controls for anti–IFN-g and anti–IL-4, whereas cells in boxes (ii), (iv), (vi), and (viii) were stained791 Xu et al.
ern blot, we again failed to detect ST2L message in a panel
of Th1 lines. In contrast, the message was readily demon-
strated in four Th2 lines.
Regulation and Expression of ST2L Gene in Th1s and
Th2s. We next investigated the regulation and expression
of ST2L in Ths by various immunological stimuli. In con-
trast to Th2s that expressed ST2L constitutively and stably,
Th1s did not express ST2L even when cultured with Con
A, IL-1b, IL-2, IL-4, IFN-g, or with anti–IFN-g or anti–
IL-4 antibodies. After incubation with IL-5 or anti-CD3
antibody, Th1s expressed a weak ST2L message transiently
at 3 and 6 h after activation, respectively (Fig. 2 a); but this
disappeared completely by 12 h (data not shown). The ex-
pression of ST2L in Th2s was not affected by these stimuli
(Fig. 2 a). ST2L is a delayed, early proliferative response
gene in BALB/c-3T3 cells induced by serum factors (10–
13). We therefore examined the regulation of ST2L ex-
pression in T cells by serum. Cells were rested for 48 h in
serum-free medium and then cultured in medium contain-
ing 20% FCS. The expression of ST2L in Th2s was dimin-
ished when cultured in serum-free medium, but restored
soon after the addition of serum. In contrast, no ST2L mes-
sage was detectable in Th1s before or 6 h after addition of
serum (Fig. 2 b).
Flow Cytometric Analysis of Cell Surface Expression of
ST2L. To study the location and function of the mole-
cule, a polyclonal rabbit antibody corresponding to the hy-
drophilic region of the extracellular domain of ST2L was
raised. Th2 clones, but not Th1 clones, were positively la-
beled with this antibody. The staining was clearly detected
on the cell surface (Fig. 3 a). Single cell three-color flow
cytometric analysis demonstrated that ST2L coexpressed
with IL-4, but not with IFN-g in cloned T cell lines (Fig.
3 b). We then determined whether this staining pattern also
occurs in cells derived from naive T cells. Splenic CD41 T
cells from the OVA TCR-a/b transgenic mice (D011.10)
were driven to the Th1 or the Th2 lineage in vitro in a 6-d
culture and stimulated with PMA and ionomycin for 4 h
(17). Staining for ST2L and intracellular IFN-g and IL-4
demonstrated that the Th1 line expressed no ST2L or IL-4,
but showed intracellular staining for IFN-g. In contrast,
the Th2 line expressed strong ST2L and IL-4 staining, but
produced no detectable IFN-g (Fig. 3 c).
Anti-ST2L Antibody and Complement Selectively Lysed
Th2s. We next examined the effect of anti-ST2L anti-
body on Th1 and Th2 clones in vitro. A panel of Th1 and
Th2 clones were incubated in vitro with graded concentra-
tions of anti-ST2L or normal rabbit IgG, and then with or
without complement. In the presence of complement,
anti-ST2L antibody strongly lysed the Th2 clones, but had
only a modest effect on Th1 clones (Table 1).
Effect of anti-ST2L Antibody on Leishmania Infection.
We next investigated the effect of anti-ST2L antibody in
vivo. BALB/c mice are genetically highly susceptible to in-
fection by the protozoan parasite, L. major. The disease
progression can be modified and resistance induced by a
variety of immunological manipulations (for review see ref-
erence 23). Disease progression and resistance are associated
with the preferential development of Th2s or Th1s, respec-
tively (for review see reference 24). Fig. 4 demonstrates
that BALB/c mice infected with L. major and treated with
anti-ST2L antibody developed significantly smaller lesions
(Fig. 4 a) and three orders of magnitude less parasite load
(Fig. 4 b) compared with mice treated with control rabbit
IgG. Draining lymph node cells from the anti-ST2L–
treated mice produced significantly more IFN-g, but less
IL-4 and IL-5 compared with cells from control IgG-
treated mice (Fig. 4 c). IL-12 levels were not affected.
Effect of Anti-ST2L Antibody on Collagen-induced Arthri-
tis. Collagen-induced arthritis (CIA) in susceptible DBA/1
mice is a predominantly Th1-mediated disease (25–27), the
immunopathogenesis of which closely resembles clinical
rheumatoid arthritis (28, 29). We therefore examined
whether administration of anti-ST2L antibody could mod-
ify CIA. Mice injected intradermally with type II collagen
in Freund’s complete adjuvant developed arthritis when
challenged intraperitoneally 21 d later with collagen. Inci-
with rabbit anti-ST2L, anti–IFN-g, and anti–IL-4 antibodies. Cells in boxes (i), (ii), (v), and (vi) have been gated for positive expression of ST2L when
stained with anti-ST2L antibody (R3, black) relative to negative staining with control rabbit IgG (R2, gray). Colocalization of R2 and R3 depicts negative
expression of ST2L. Cytokines in the culture supernatants (48 h) of T cell clones (106/ml) stimulated with specific antigen and irradiated antigen-present-
ing cells were (IFN-g versus IL-4, ng/ml): X4, 5.2 versus ,0.02; X12, ,0.01 versus 0.25. (c) Three-color flow cytometric analysis of Th1s and Th2s de-
rived from naive T cells. CD41 splenic T cells from D011.10 TCR-a/b transgenic mice were driven to Th1 or Th2 subsets in a 6-d culture. They were
then stimulated with PMA/ionomycin, stained, and analyzed as in b. Cytokines in the culture supernatants (day 3) were (IFN-g versus IL-5, ng/ml): Th1
line, 2.6 versus ,0.02; Th2 line, ,0.01 versus 0.52. Results are representative of five experiments.
Table 1. Effect of Anti-ST2L Antibody on T Cells In Vitro
Treatment
of cells
Th1 (X4)
percent viability
Th2 (X12)
percent viability
Anti-ST2L 1 C9 85.2 6 2.1 9.7 6 0.5*
Anti-ST2L alone 94.9 6 3.5 95.2 6 4.6
Normal IgG 1 C9 95.9 6 2.7 94.6 6 3.3
Normal IgG alone 95.0 6 2.9 97.2 6 5.8
Medium alone 96.2 6 3.5 95.8 6 3.9
Th1s and Th2s were incubated with 400 mg/ml of antibody and then
with or without complement (C9). The cell viability was determined
microscopically. At this concentration, in the absence of complement,
anti-ST2L antibody, but not normal IgG, also partially suppressed the
proliferation and cytokine production by Th2s in vitro in response to
specific antigen and antigen-presenting cells. The antibody did not af-
fect the proliferation of Th1s (data not shown). Data are mean 6 SEM,
n 5 3. *P ,0.001 compared with medium control. Similar results were
obtained for three other Th1 and Th2 clones.792 T Helper Cell Type 2 Surface Marker
dence and severity of disease development were markedly
enhanced in mice that received daily intraperitoneal injec-
tions of anti-ST2L antibody from day 22, compared with
controls that received normal IgG (Fig. 5, a–c). On stimula-
tion with collagen in vitro, spleen cells from antibody-
treated mice also produced significantly stronger prolifera-
tive response and more IFN-g and IL-6 compared with
cells from control mice (Fig. 5 d).
Discussion
Data presented here demonstrate that ST2L is a stable
cell surface marker expressed strongly on Th2s, but not
Th1s. Furthermore, antibody against ST2L selectively lysed
Th2s in vitro and enhanced Th1 response in vivo. Thus,
anti-ST2L antibody increased resistance to L. major infec-
tion in the highly susceptible BALB/c mice. It also exacer-
bated CIA in DBA/1 mice. These effects were accompa-
nied by enhanced IFN-g production and diminished IL-4/
IL-5 synthesis. It is likely that the antibody exerted its effect
through direct depletion of Th2s in vivo and hence the
regulation of Th1s by Th2s (1–3), such that the balance is
shifted towards Th1s. This is consistent with the observa-
tion that treatment with anti-ST2L antibody in the L. ma-
jor–infected mice did not significantly alter the production
of IL-12, a cytokine principally secreted by macrophages
and a major mediator of Th1 differentiation (30). Such a
mechanism would also explain the immediate effect of the
antibody seen in the CIA model (Fig. 5).
ST2L is not detectable on B cells, a macrophage cell line
Figure 5. Anti-ST2L antibody exacerbated
collagen-induced arthritis in DBA/1 mice. Mice
were primed (day 221) and challenged (day 0)
with collagen and injected with anti-ST2L anti-
body or normal rabbit IgG daily from day 1. (a)
Incidence rate (percent), (b) clinical score, and
(c) number of arthritic paws. Data are mean 6
SEM, n 5 15. Mice (n 5 4) were killed 48 h af-
ter antibody treatment, spleen cells were pooled
and cultured with collagen (50 mg/ml) for 48–
96 h, and culture supernatants were assayed for
cytokines by ELISA. *P ,0.05, **P ,0.01 (two
sample t test). IL-4 and IL-5 were not detected
(,20 pg/ml). T cell proliferation was expressed
as [3H]thymidine uptake in triplicate cultures
(mean cpm 3 103 6 SEM): antibody treated,
52.8 6 6.8; control, 27.8 6 1.1 (P ,0.05).
Figure 4. Effect of anti-ST2L antibody on L. major infection. BALB/c
mice were infected in the footpad with the parasite and injected intraperi-
toneally with anti-ST2L antibody or normal rabbit IgG. Antibody-treated
mice developed significantly smaller lesions (a) and parasite loads (b) com-
pared with controls, n 5 10. Experiments were terminated when control
mice developed necrotic lesions as required by the United Kingdom
Home Office guidelines. (c) Draining lymph node cells were pooled (n 5
10) and cultured with leishmanial antigen, and supernatants from triplicate
cultures assayed for cytokines. There was no significant difference in the
T cell proliferative response between the two groups of mice (data not
shown). Results are representative of two experiments.793 Xu et al.
(J774), or a CD81 cell line (CTLL) (data not shown). The
developmental stage of Th2s at which ST2L expression oc-
curs is currently unclear. However, the expression of ST2L
is clearly associated with the production of IL-4 and IL-5.
It has been reported that the transcription factor GATA-3
is necessary and sufficient for Th2 cytokine gene expression
in CD41 T cells (31). Furthermore, the promoter region of
ST2L contains the GATA consensus binding motif (32). It
is therefore possible that GATA-3 influences Th2 functions
by directing the transcription of ST2L. The ontogeny of
Th2s in relation to ST2L and the sequence of events lead-
ing to the induction of ST2L and Th2 cytokine production
remain to be explored.
It is important to note that a soluble form (ST2, mol wt:
37-kD) without the trans-membrane domain (10–13, 33) is
also transcribed from the same gene by differential splicing,
determined by the use of alternate promoters (13, 32). We
have found that all Th2s expressing ST2L gene also express
ST2 message (data not shown). The receptor-like nature of
ST2L suggests the existence of a ligand that is yet to be
identified. It may be that the membrane bound form
(ST2L) and the soluble form (ST2) act as regulators of Th2
functions. Furthermore, they should serve as important bi-
ologically relevant tools for investigating gene regulation
for the expression of a trans-membrane versus a secreted
form of a protein.
The in vivo effect of anti-ST2L antibody in mice sug-
gests that selective modulation of ST2L expression could
have considerable therapeutic potential. The close associa-
tion of ST2L expression with IL-4/IL-5 production sug-
gests that the membrane-bound ST2L molecule could be a
potentially important therapeutic target for allergic re-
sponses such as asthma. ST2L is present in humans (34) and
its relevance in human T cell functions is currently being
addressed.
In conclusion, we have identified a stable cell surface
marker distinguishing Th2s from Th1s. Furthermore, an
antibody against this molecule has a range of biological ef-
fects in vivo including infection and inflammation. Thus,
this marker will not only facilitate functional analysis of
Th1 and Th2 interaction, it may also be a potential target
for therapeutic intervention for some of the important dis-
eases.
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